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Anticoagulant treatment with phenprocoumon is challenging because of the narrow therapeutic range and 
the wide inter- and intra-patient variability in dose response. Frequent monitoring of the international 
normalized ratio (INR) is therefore required. Polymorphisms in two genes, CYP2C9 and VKORC1 
explain approximately one third of the variation in dose requirements [1-3]. CYP2C9 encodes the main 
metabolizing enzyme of coumarins, the cytochrome P450 2C9 enzyme (CYP2C9), while VKORC1 
encodes the pharmacodynamic target enzyme for coumarins, vitamin K epoxide reductase multiprotein 
complex 1 (VKORC1). 
Earlier this year, we found that in the first month of acenocoumarol therapy, the risk of 
underdosing is highest in patients with a VKORC1 wild-type [4]. This increased risk of a subtherapeutic 
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INR was also seen in months 2 and 3, but not after the third month of coumarin treatment. In addition, the 
risk of overdosing was highest in patients with a VKORC1 TT genotype in the first 6 months. The effect 
of CYP2C9 genotype on under- or overdosing of acenocoumarol was smaller than the effect of VKORC1 
and this effect was only found in the first month of therapy and not after the initiation period [4]. This has 
not been investigated for phenprocoumon yet. The aim of this study was therefore to examine the 
association of CYP2C9 and VKORC1 polymorphisms with the risk of over- and underanticoagulation 
after the initiation period of phenprocoumon. 
 To investigate this, we looked at data from two different studies, the pre-EU-PACT study 
[5] and the study of Schalekamp et al. [6]. The study protocols of both studies were approved by a 
Medical Ethics Committee (Leiden University Medical Center, Leiden for pre-EU-PACT, Utrecht 
Medical Centre, Utrecht for the study of Schalekamp) and patients provided informed consent before 
study inclusion. All procedures were conducted in accordance with the Helsinki Declaration. More details 
about the design and data collection in both studies can be found elsewhere [4]. 
We examined the occurrence of at least one INR <2, >3.5 or >6.0 in several time periods up to 1.5 years 
after treatment initiation and tested for differences among the genotypes with chi-square analysis. The 
time periods we used were: 0-1 month (day 1-30), 1-3 months (day 31-90), 3-6 months (day 91-180), 6-9 
months (day 181-270), 9-12 months (day 271-360), 12-15 months (day 361-450) and 15-18 months (day 
451-540) after treatment initiation. We also looked at the time within, below and above the therapeutic 
range, since this method is more robust when the frequency of INR measurements differs between 
patients. All analyses were performed using SPSS 18.0.  
In total, 794 phenprocoumon users from the two studies [5,6] were eligible for analyses in this 
study. Patient characteristics and genotypes of all 794 patients are shown in the Supplement Table 1. Data 
on height and weight were only available in the Pre-EU-PACT study (n=486). The most frequent 
indication for phenprocoumon treatment was atrial fibrillation. The average number of INR 
measurements per time period ranged from 3.4 to 5.5. Only data of patients using phenprocoumon during 
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the entire time period were included in the analysis of that period. The maximum follow-up in the 
Schalekamp study was six months (n=308). 
Significant differences in out-of-range INR values between the genotypes were only found during 
the first month of phenprocoumon therapy. In the first month, 89% of the patients with a VKORC1 wild-
type had at least one subtherapeutic INR. This frequency was significantly lower among patients with CT 
(76%, p<0.001) and TT (50%, p<0.001). Supratherapeutic INR values occurred in 33% of the VKORC1 
wild-type patients, versus 48% (p<0.001) and 66% (p<0.001) in patients with a CT or TT genotype, 
respectively. Of the wild-type patients, 3% had at least one INR>6. This percentage was increased in 
patients with a TT genotype (17%, p<0.001), but there was no statistically significant difference for 
patients with a CT genotype (6%, p=0.12).  
Occurrences of subtherapeutic INR values or INR values >6 were not significantly different 
among the CYP2C9 genotypes. However, INR values >3.5 occurred more often in carriers of a 
CYP2C9*3 allele (62%, p<0.001) or a CYP2C9*2 allele (52%, p=0.01) than in wild-type patients (40%). 
For both VKORC1 and CYP2C9 genotypes, no significant differences in out-of-range INRs were found 
after the first month. The risk of out-of-range INRs for the different periods and genotypes are shown in 
the Supplement (Supplement Figures 1-4). 
Similar results were obtained in the analyses of time within, below and above therapeutic INR 
range (see Figure 1). In the first month, time below therapeutic INR range was longest in VKORC1 and 
CYP2C9 wild-type patients (up to 33%) and time above therapeutic INR range was longest in VKORC1–
TT and CYP2C9*3 carriers (up to 37%). The risk of having at least one INR<2 did not vary significantly 
among the CYP2C9 genotypes, but the time spent below therapeutic INR range was significantly shorter 
in *2 carriers (19%) and *3 carriers (14%) than in wild-type patients (26%, p<0.001). No significant 
differences were found after month 1 of the treatment. 
Our study demonstrated that in the first month of phenprocoumon therapy, the risk of 
underdosing is highest in patients with VKORC1 and CYP2C9 wild-types. In addition, the risk of 
overdosing was highest in patients with a VKORC1 TT genotype or carriers of a CYP2C9 variant allele. 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 International Society on Thrombosis and Haemostasis 
These results correspond with the results we have seen for acenocoumarol users, as described in a 
previous article [4]. However, the results beyond the first month of treatment are not similar. Specifically, 
while there were no differences in the risk of out-of-range INRs between the different genotypes after the 
first month of phenprocoumon therapy, there were differences in risk between the VKORC1 genotypes 
up to the sixth month of acenocoumarol treatment. 
A limitation of this study is the fact that the Pre-EU-PACT study contained retrospective data [5]. 
The data of Schalekamp et al., however, was collected prospectively [6]. Data for a specific time period 
was only used in the analysis if the patient used phenprocoumon for this entire period. Because very 
unstable patients are expected to stop the therapy early, this patient group might be underrepresented in 
our study. 
Information about the patient’s genotype can be used to predict the right dose of phenprocoumon 
[5]. Carriers of a VKORC1 or CYP2C9 variant allele require a lower dose and have an increased risk of 
supratherapeutic INR values. If these patients are genotyped before treatment initiation, they could be 
treated with a lower dose, thereby decreasing the risk of overanticoagulation. In both this study and our 
previous study on acenocoumarol, we also found an increased risk of a subtherapeutic INR in VKORC1 
and CYP2C9 wild-type patients during the first month. Information about the patient’s genotype could 
therefore also be used to identify patients need a higher dose to decrease the risk of complications from 
underdosing. In this way, genetic information could be used to improve the safety and efficacy of 
anticoagulation treatment in both wild-type patients and variant carriers. The relevance of 
pharmacogenetic information for phenprocoumon users, however, seems to be limited to the first month 
of treatment. 
Phenprocoumon has a longer elimination half life than acenocoumarol (110-130 hours versus 6-8 
hours) [3,7]. Treatment with phenprocoumon is therefore somewhat more stable and patients on 
phenprocoumon spend more time within the therapeutic INR range than patients on acenocoumarol [8]. 
This might be a reason why only acenocoumarol users –and not phenprocoumon users- show differences 
between the genotypes in the risk of out-of-range INRs after the first month of treatment. 
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The results of this study suggest that pharmacogenetic information might help to prevent 
subtherapeutic or supratherapeutic INRs in the first month of phenprocoumon therapy and thereby reduce 
the risk of adverse events. The value of this information after the first month of phenprocoumon treatment 
appears to be limited. Currently, clinical trials are underway to investigate the effectiveness and cost-
effectiveness of a genotype-guided dosing regimen versus a standard dosing regimen [9,10]. 
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Figure Legends 
 
Figure 1. Percentage time in different INR ranges during the first month of phenprocoumon use. A: 
VKORC1 genotypes B: CYP2C9 genotypes 
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